Read the full article now!
For years the bundling of radiopharmaceuticals with the technical portion for one payment to the provider has been a bone of contention. Bundling the radiopharmaceutical and treating it as a consumable rather than a drug, means that the provider can lose money on every scan done with necessary high ticket radiopharmaceuticals. The question is whether this approach to Medicare cost-cutting is hurting the use of nuclear medicine and limiting the development of new tracers? In the end, Medicare may save a few dollars but, the question as to the quality of patient care decisions driven by a need to at least break even is still open.
Read the full article in this month’s issue of HealthCare Business News